Daré Bioscience, Inc.

Daré Bioscience, Inc. is a biopharmaceutical company dedicated to advancing innovative products for women's health. Headquartered in San Diego, California, the company's mission is to identify, develop, and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes, and facilitate convenience for women. It aims to close the gap between promising science and real-world solutions in areas that have historically been underserved in healthcare.

Daré Bioscience focuses on a broad range of women's health market segments, including contraception, fertility, vaginal health, sexual health, menopause, pelvic pain, and infectious disease. Its portfolio includes XACIATO (clindamycin phosphate) vaginal gel 2%, an FDA-approved treatment for bacterial vaginosis, which is licensed to Organon. The company's pipeline features several investigational candidates, such as Ovaprene, a hormone-free monthly intravaginal contraceptive in Phase 3 clinical development; DARE to PLAY™ Sildenafil Cream for female sexual arousal disorder, available via 503B compounding; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. Other programs include DARE-HPV for high-risk HPV infection and DARE-PTB1 for preterm birth risk.

Under the leadership of President and CEO Sabrina Martucci Johnson, Daré Bioscience continues to advance its pipeline and commercialization efforts. Recent activities include reporting full-year 2025 financial results and a business update in March 2026, and the commercial rollout of DARE to PLAY™ Sildenafil Cream, with revenue expected in Q2 2026. The company has also secured significant non-dilutive grant funding from organizations like the Gates Foundation, NIH, and ARPA-H to support its research and development initiatives. Enrollment for the Ovaprene Phase 3 study is anticipated to conclude in 2026, and the FDA cleared the IND for a Phase 2 clinical study of DARE-HPV in February 2026.